Britain and America have announced a important trade agreement that will ensure zero import taxes on British drug products going into the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to raise expenditure on drugs through the National Health Service (NHS). This commitment secures that tariffs on these vital exports will remain at zero for a period of 36 months.
This development comes after recent threats to dramatically increase import taxes on patented pharmaceutical products, with increases floated up to double the cost.
"This agreement between the Britain reinforces the international landscape for innovative medicines and establishes much-needed equity to U.S.–U.K. drug exports," a statement noted.
Commercial Impact
Drugs represent one of the UK's largest goods shipped to the United States, which is easily the primary market for large British pharmaceutical firms.
Statistics show that in the one-year period prior to last September, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This value made up nearly one-fifth of British export trade in that period.
"This deal secures work, boosts capital expenditure and facilitates the UK to emerge as a global hub for medical research," the Business and Trade Secretary commented.
Specific UK Commitments
The deal involves several specific changes from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to raise overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, repayments topped 20%.
Recent Tensions
This agreement comes amid a ongoing row between the pharmaceutical industry and the British authorities over spending levels and approval rates.
The disagreement were exacerbated by claims that US patients were charged several times more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been delayed or scrapped, while major expansions have been directed toward US facilities.
A senior figure acknowledged that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a share of its overall budget over the previous ten-year period.
